CD40 and AIDS: In the case of acquired immunodeficiency syndrome (AIDS)-related non-Hodgkin’s lymphoma, which includes Burkitt’s lymphoma and DLBCL, there was a specific reduction in EVs expressing PD-L1, CD40, CD40-ligand (CD40L), or tumour necrosis factor receptor II (TNF-RII) after treatment with rituximab and/or combination chemotherapy[78].